Navigation Links
Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
Date:8/7/2008

one repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially f
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Alseres Pharmaceuticals, Inc.s Chairman, Peter Savas, Reviews Companys Progress in its Annual Letter to Stockholders
2. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
3. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
4. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
5. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
6. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
7. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
10. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
11. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2EyeScience 28TM 29 Announces New Program to Improve Patient Compliance and Practice Profits 6181 1EyeScience 28TM 29 Announces New Program to Improve Patient Compliance and Practice Profits 6181 2EyeScience 28TM 29 Announces New Program to Improve Patient Compliance and Practice Profits 6181 3Nobel laureate claims the 2010 Herbert Tabor Lectureship 10699 1Nobel laureate claims the 2010 Herbert Tabor Lectureship 10699 2Trial Data on Anti Seizure Drug Might Have Been Manipulated 3A Report 61184 1Trial Data on Anti Seizure Drug Might Have Been Manipulated 3A Report 61184 2Trial Data on Anti Seizure Drug Might Have Been Manipulated 3A Report 61184 3